Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy

Okuma, Yusuke; Ko, Ryo; Shukuya, Takehito; Tateishi, Kazunari; Imai, Hisao; Iwasawa, Shunichiro; Miyauchi, Eisaku; Kojima, Takao; Fujita, Yuka; Hino, Toshihiko; Yamanda, Shinsuke; Suzuki, Tamio; Fukuizumi, Aya; Sakakibara, Tomohiro; Harada, Toshiyuki; Morita, Satoshi; Kobayashi, Kunihiko; Nukiwa, Toshihiro; Takahashi, Kazuhisa

doi:10.1016/j.lungcan.2020.08.014

Cited by 8 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to being a nutritional indicator, albumin also acts as a parameter representing inflammatory dynamics, and it is affected by several factors, such as extracellular fluid volume, dehydration status, and inflammatory dynamics. Our results corroborate those of a previous study by Okuma et al, in which hypoalbuminemia was found to be an adverse prognostic factor for OS in advanced thymic carcinoma 17 . Notably, the present study demonstrated that an intermediate/poor LIPI was an independent negative prognostic factor for both PFS and OS.…”

Section: Discussionsupporting

confidence: 92%

“…17,18 In addition, hypoalbuminemia was identified as an independent prognostic factor. 17 These findings indicate that in patients with advanced or metastatic thymic carcinoma, clinical characteristics and laboratory findings may have prognostic potential superior to that of chemotherapy regimen. Thus, in the present study, we applied the LIPI and evaluated its clinical utility as a novel prognostic marker in patients with thymic carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a multicenter, retrospective study on advanced thymic carcinoma, involving a comparatively large sample size, was conducted in Japan 17‐19 . The results of the study revealed no significant difference in OS between the first‐line chemotherapy regimens, whereas tumor staging (Masaoka–Koga stage IVa) was an independent prognostic factor for OS 17,18 . In addition, hypoalbuminemia was identified as an independent prognostic factor 17 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: The prognostic implications of palliative chemotherapy for advanced or recurrent thymic carcinomas require full elucidation. The lung immune prognostic index (LIPI) is a novel prognostic index whose effectiveness has recently been reported in lung cancer patients. This study aimed to evaluate the clinical value of the LIPI in advanced or recurrent thymic carcinoma patients. Methods: We retrospectively analyzed 41 advanced or recurrent thymic carcinoma patients undergoing palliative chemotherapy between January 2001 and December 2020. Survival-time analysis was conducted using the Kaplan-Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to investigate the predictive and/or prognostic value of the LIPI. Results: Median progression-free survival (PFS) for first-line chemotherapy and overall survival (OS) were significantly longer in the good-LIPI group (LIPI: 0) than in the intermediate/poor-LIPI group (LIPI: 1 or 2) (PFS: 13.4 vs. 6.8 months, p = 0.025; OS: 48.2 vs. 28.9 months, p = 0.00506). Multivariate analysis revealed that intermediate/ poor LIPI was the adverse prognostic factor for PFS. With regard to OS, serum albumin <3.5 g/dl and an intermediate/poor LIPI were identified as independent adverse prognostic factors. Conclusions: Our study indicates that the LIPI is a potential prognostic marker in patients with advanced or recurrent thymic carcinoma undergoing palliative chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is for this reason that surgical cases after neoadjuvant chemoradiotherapy treatment for advanced thymic tumors may not be rare 16–17 . However, preoperative chemoradiotherapy may cause immune impairment and prolonged wound healing 13,18–20 . Thus, this retrospective study investigated details of the clinical course of patients with advanced thymic tumors undergoing SVC replacement surgery after neoadjuvant chemoradiotherapy, together with long‐term prognosis.…”

Section: Introductionmentioning

confidence: 99%

Surgical feasibility and long‐term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy

et al. 2021

Thoracic Cancer

View full text Add to dashboard Cite

Background The aim of this study was to investigate the long‐term outcome of superior vena cava (SVC) replacement after chemotherapy or chemoradiotherapy for advanced thymoma. Methods The medical information of patients with advanced thymoma who underwent thymoma resection and SVC replacement in Beijing Tongren Hospital from 2002 to 2017 were reviewed. We compared surgical outcomes, postoperative complications and long‐term prognosis in the chemoradiotherapy + surgery group (CRT + surgery group, 19 cases) and the surgery group (26 cases). Results The operation time (486.05 ± 148.01 vs. 370.77 ± 124.32 min; p = 0.007) and intraoperative blood loss (1400 ml [IQR 1125–2105 ml] vs. 855 ml [IQR 555–1682.5 ml], p = 0.036), poor wound healing (three cases [15.79%] vs. zero cases [0.0%], p = 0.036) in the CRT + surgery group were significantly higher than those of the surgery group. There was no significant difference between the CRT + surgery group and the surgery group in postoperative chest tube drainage time, hospitalization time, postoperative arrhythmia and incidence of pneumonia. Kaplan Meier analysis showed that the recurrence‐free survival (RFS) curves of the CRT + surgery group patients were better than those of the surgery group (p = 0.031). However, overall survival (OS) between the two groups was not significantly different (p = 0.069). Conclusions Thymoma resection and SVC replacement is feasible for patients undergoing preoperative induction chemotherapy or chemoradiotherapy for advanced thymoma. Although patients in the CRT + surgery group had a longer operation time and increased intraoperative bleeding, the RFS rate seemed to be better than that in the surgery group.

show abstract

“…Regarding clinical course, data on the types of rst line chemotherapy regimen, treatment response, palliative intent radiotherapy, and survival time were collected. The treatment response for rst line chemotherapy was evaluated according to the revised Response Evaluation Criteria in Solid Tumors guidelines (v.1.1) [14] . Overall survival (OS) was de ned as the period from initiation of chemotherapy to either a fatal event or censored observation.…”

Section: Data Collectionmentioning

confidence: 99%

Prognostic Factor in Patients with Advanced, Inoperable Thymic Carcinoma: An Application of the Lung Immune Prognostic Index

Araki

Tateishi

Komatsu

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The prognostic implications of palliative chemotherapy for advanced or recurrent thymic carcinomas require full elucidation. The lung immune prognostic index (LIPI) is a novel prognostic index whose effectiveness has recently been reported in lung cancer patients. This study aimed to evaluate the LIPI’s clinical value in advanced or recurrent thymic carcinoma patients. Methods: We retrospectively analyzed 41 advanced or recurrent thymic carcinoma patients undergoing palliative chemotherapy between January 2001 and December 2020. Survival-time analysis was conducted using the Kaplan–Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to investigate the LIPI’s predictive and/or prognostic value.Results: Median progression-free survival (PFS) for first line chemotherapy and overall survival (OS) were significantly longer in the good-LIPI group (LIPI: 0) than in the intermediate/poor-LIPI group (LIPI: 1 or 2) (PFS: 13.4 vs. 6.8 months, p=0.0425; OS: 48.2 vs. 28.9 months, p=0.00506.). Multivariate analysis revealed that serum albumin <3.5 g/dL and an intermediate/poor LIPI were independent adverse prognostic factors for OS. Moreover, an intermediate/poor LIPI was the only adverse prognostic factor for PFS. Conclusions: Our study indicates that the LIPI is a potential prognostic marker in patients with advanced or recurrent thymic carcinoma undergoing palliative chemotherapy.

show abstract

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy

Cited by 8 publications

References 30 publications

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy

Surgical feasibility and long‐term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy

Prognostic Factor in Patients with Advanced, Inoperable Thymic Carcinoma: An Application of the Lung Immune Prognostic Index

Contact Info

Product

Resources

About